Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAG1 gene therapy trial in RAG1-deficient severe combined immunodeficiency
NL-OMON59880Phase 1Suspended
- Sponsor
- Videja Therapeutics
- Start
- Jul 2021
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MB-110 in severe combined immunodeficiency (SCID), sponsored by Videja Therapeutics. Primary endpoints: Overall survival, Immune reconstitution at Month 6 and 1 more. Started Jul 2021; status: suspended.
02
Drugs
MB-110
03
Conditions
severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NL-OMON59880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59880.